UNSPSC 51432110: Guanethidine monosulfate

This classification denotes an antihypertensive agent with the molecular structure C10H22N4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5UBY8Y002G chemically known as guanidine, (2-(hexahydro-1(2h)-azocinyl)ethyl)-, sulfate (1:1), but more commonly known as guanethidine monosulfate, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine monosulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14033MIG.

Most nations, for tariff and trade purposes, schedule guanethidine monosulfate under HS 29339990 and SITC 51577. As of Q4 2014, GUANETHIDINE MONOSULFATE remains US FDA's Preferred Term for this commodity. Guanethidine monosulfate bears US NLM identifiers UMLS ID C0282190 and NCI Concept Code C65831. SMILES: C1CCCN(CCC1)CCNC(=N)N.OS(=O)(=O)O.

UNSPSC 51432110 Guanethidine monosulfate is a Commodity code representing a specific pharmaceutical active ingredient used in antihypertensive treatments. State and local governments procure this and related medications primarily as finished goods through emergency medical services agencies, health departments, and cooperative purchasing alliances serving multiple jurisdictions. Recent solicitations show demand concentrated in advanced life support medication supplies for first-responder agencies and in generic multi-source pharmaceutical procurement programs that bundle hundreds of therapeutics for distribution across state and local health facilities. The issuing bodies include city purchasing departments managing emergency services procurement, state health agencies conducting multi-jurisdiction cooperative purchasing, and regional alliances aggregating demand across participating states and localities.

The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (Bid No. 26-P-00188, IFB, response due April 8, 2026) for Tampa Fire Rescue, specifying four medication line items including epinephrine and diltiazem but not explicitly naming guanethidine; the estimated contract value was $40,000 with a one-year term and three optional one-year renewals, and included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating jurisdictions through three authorized wholesalers, with a two-year contract term beginning July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of three wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in March 2026 exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. Recent activity spans Florida, Texas, and the Upper Midwest, with municipal fire-rescue operations and state health agencies as primary buyers.